9,499 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by Vise Technologies Inc.

Vise Technologies Inc. acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 9,499 shares of the biopharmaceutical company’s stock, valued at approximately $743,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. E Fund Management Co. Ltd. bought a new stake in shares of Halozyme Therapeutics during the second quarter worth $455,000. Aurora Investment Counsel bought a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $1,427,000. Great Lakes Advisors LLC bought a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $2,821,000. Diversify Advisory Services LLC bought a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $2,768,000. Finally, Pacific Wealth Management acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at $423,000. Institutional investors own 97.79% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on HALO shares. TD Cowen boosted their price objective on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Wells Fargo & Company lifted their price target on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Morgan Stanley reduced their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Finally, Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $91.20.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $108.17 on Monday. The firm has a market cap of $12.28 billion, a PE ratio of 32.29, a price-to-earnings-growth ratio of 0.43 and a beta of 0.85. The firm’s fifty day moving average is $83.19 and its 200-day moving average is $73.74. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $108.49.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.Halozyme Therapeutics’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00. Following the sale, the chief executive officer owned 767,780 shares in the company, valued at approximately $79,987,320.40. The trade was a 2.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the sale, the director directly owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 64,103 shares of company stock valued at $5,226,496. 2.50% of the stock is currently owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.